Evidence map›Paper›PMID 24453783›Full record

ArticleInternational journal of MS care2013

Treatment discontinuation and disease progression with injectable disease-modifying therapies: findings from the north american research committee on multiple sclerosis database.

Robert J Fox, Amber R Salter, Tuula Tyry, Jennifer Sun, Xiaojun You, Genevieve Laforet, Denise Campagnolo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of MS care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis.European journal of hospital pharmacy : science and practice · 2019
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Robert J FoxMellen Center for Multiple Sclerosis, Neurological Institute, and the Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA (RJF); the University of Alabama at Birmingham, Birmingham, AL, USA (ARS); Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA (TT); Biogen Idec Inc, Weston, MA, USA (JS, XY, GL, DC); the University of Massachusetts Medical School, Worcester, MA, USA (GL); and the University of Arizona College of Medicine, Phoenix, AZ, USA (DC).
Amber R SalterMellen Center for Multiple Sclerosis, Neurological Institute, and the Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA (RJF); the University of Alabama at Birmingham, Birmingham, AL, USA (ARS); Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA (TT); Biogen Idec Inc, Weston, MA, USA (JS, XY, GL, DC); the University of Massachusetts Medical School, Worcester, MA, USA (GL); and the University of Arizona College of Medicine, Phoenix, AZ, USA (DC).
Tuula TyryMellen Center for Multiple Sclerosis, Neurological Institute, and the Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA (RJF); the University of Alabama at Birmingham, Birmingham, AL, USA (ARS); Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA (TT); Biogen Idec Inc, Weston, MA, USA (JS, XY, GL, DC); the University of Massachusetts Medical School, Worcester, MA, USA (GL); and the University of Arizona College of Medicine, Phoenix, AZ, USA (DC).
Jennifer SunMellen Center for Multiple Sclerosis, Neurological Institute, and the Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA (RJF); the University of Alabama at Birmingham, Birmingham, AL, USA (ARS); Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA (TT); Biogen Idec Inc, Weston, MA, USA (JS, XY, GL, DC); the University of Massachusetts Medical School, Worcester, MA, USA (GL); and the University of Arizona College of Medicine, Phoenix, AZ, USA (DC).
Xiaojun YouMellen Center for Multiple Sclerosis, Neurological Institute, and the Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA (RJF); the University of Alabama at Birmingham, Birmingham, AL, USA (ARS); Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA (TT); Biogen Idec Inc, Weston, MA, USA (JS, XY, GL, DC); the University of Massachusetts Medical School, Worcester, MA, USA (GL); and the University of Arizona College of Medicine, Phoenix, AZ, USA (DC).
Genevieve LaforetMellen Center for Multiple Sclerosis, Neurological Institute, and the Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA (RJF); the University of Alabama at Birmingham, Birmingham, AL, USA (ARS); Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA (TT); Biogen Idec Inc, Weston, MA, USA (JS, XY, GL, DC); the University of Massachusetts Medical School, Worcester, MA, USA (GL); and the University of Arizona College of Medicine, Phoenix, AZ, USA (DC).
Denise CampagnoloMellen Center for Multiple Sclerosis, Neurological Institute, and the Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA (RJF); the University of Alabama at Birmingham, Birmingham, AL, USA (ARS); Barrow Neurological Institute of St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA (TT); Biogen Idec Inc, Weston, MA, USA (JS, XY, GL, DC); the University of Massachusetts Medical School, Worcester, MA, USA (GL); and the University of Arizona College of Medicine, Phoenix, AZ, USA (DC).
Biogen (Switzerland) · CHCase Western Reserve University · USSt. Joseph's Hospital and Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Injectable first-line disease-modifying therapies (DMTs) for multiple sclerosis (MS) are generally prescribed for continuous use. Accordingly, the various factors that influence patient persistence with treatment and that can lead some patients to switch medications or discontinue treatment may affect clinical outcomes. Using data from the North American Research Committee on Multiple Sclerosis (NARCOMS) database, this study evaluated participants' reasons for discontinuation of injectable DMTs as well as the relationship between staying on therapy and sustained patient-reported disease progression and annualized relapse rates. Participants selected their reason(s) for discontinuation from among 16 possible options covering the categories of efficacy, safety, tolerability, and burden, with multiple responses permitted. Both unadjusted data and data adjusted for baseline age, disease duration, disability, and sex were evaluated. Discontinuation profiles varied among DMTs. Participants on intramuscular interferon beta-1a (IM IFNβ-1a) and glatiramer acetate (GA) reported the fewest discontinuations based on safety concerns, although GA was associated with reports of higher burden and lower efficacy than other therapies. Difficulties with tolerability were more often reported as a reason for discontinuing subcutaneous (SC) IFNβ-1a than as a reason for discontinuing IM IFNβ-1a, GA, or SC IFNβ-1b. In the persistent therapy cohort, less patient-reported disability progression was reported with IM IFNβ-1a treatment than with SC IFNβ-1a, IFNβ-1b, or GA. These findings have relevance to clinical decision making and medication compliance in MS patient care.

Identifiers

PMID24453783
PMCPMC3883017
OpenAlexW2020504874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.